[1] Ntaios, G., et al., Adipokines as mediators of endothelial function and atherosclerosis. Atherosclerosis, 2013. 227(2): p. 216-221. [2] Knudson, J.D., et al., Leptin receptors are expressed in coronary arteries, and hyperleptinemia causes significant coronary endothelial dysfunction. American Journal of Physiology-Heart and Circulatory Physiology, 2005. 289(1): p. H48-H56. [3] Santos-Alvarez, J., R. Goberna, and V. Sánchez-Margalet, Human leptin stimulates proliferation and activation of human circulating monocytes. Cellular immunology, 1999. 194(1): p. 6-11. [4] Katagiri, H., T. Yamada, and Y. Oka, Adiposity and cardiovascular disorders. Circulation Research, 2007. 101(1): p. 27-39. [5] Investigators, A., The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. American journal of epidemiology, 1989. 129(4): p. 687-702. [6] Hwang, S.-J., et al., Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation, 1997. 96(12): p.4219-4225. [7] Goldstein, B.J. and R. Scalia, Adiponectin: a novel adipokine linking adipocytes and vascular function. The Journal of Clinical Endocrinology & Metabolism, 2004. 89(6): p.2563-2568. [8] Cnop, M., et al., Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia, 2003. 46(4): p. 459-469. [9] Weyer, C., et al., Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. The Journal of Clinical Endocrinology & Metabolism, 2001. 86(5): p. 1930-1935. [10] Kumada, M., et al., Association of hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis, thrombosis, and vascular biology, 2003. 23(1): p. 85-89. [11] Ouchi, N., et al., Novel modulator for endothelial adhesion molecules. Circulation, 1999. 100(25): p. 2473-2476. [12] Taube, A., et al., Inflammation and metabolic dysfunction: links to cardiovascular diseases. American Journal of Physiology-Heart and Circulatory Physiology, 2012. 302(11):p. H2148-H2165. [13] Bonizzi, G. and M. Karin, The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends in immunology, 2004. 25(6): p. 280-288. [14] Monaco, C., et al., Canonical pathway of nuclear factor κB activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2004. 101(15): p. 5634-5639. [15] Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 1993. 362(6423): p. 801-809. [16] Loskutoff, D.J. and F. Samad, The adipocyte and hemostatic balance in obesity. Arteriosclerosis, thrombosis, and vascular biology, 1998. 18(1): p. 1-6. [17] Corgosinho, F.C., et al., The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome. Inflammation, 2012. 35(3): p.944-951. [18] Pickup, J., et al., NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia, 1997.40(11): p. 1286-1292. [19] Vozarova, B., et al., Circulating interleukin‐6 in relation to adiposity, insulin action, and insulin secretion. Obesity, 2001. 9(7): p. 414-417. [20] Pradhan, A.D., et al., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama, 2001. 286(3): p. 327-334. [21] Ohashi, K., et al., Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension, 2006. 47(6): p. 1108-1116. [22] Shibata, R., et al., Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK-and COX-2–dependent mechanisms. Nature medicine, 2005. 11(10): p.1096-1103. [23] Ikeda, Y., et al., Cyclooxygenase‐2 induction by adiponectin is regulated by a sphingosine kinase‐1 dependent mechanism in cardiac myocytes. FEBS letters, 2008. 582(7):p. 1147-1150. [24] Lawrence, T., The nuclear factor NF-κB pathway in inflammation. Cold Spring Harbor perspectives in biology, 2009. 1(6): p. a001651. [25] Bohuslav, J., et al., Regulation of an essential innate immune response by the p50 subunit of NF-kappaB. Journal of Clinical Investigation, 1998. 102(9): p. 1645.